Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

FDA approved BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis. Insmed application accepted in Japan for BRINSUPRI.

5 reports, 3 independent Updated Oct 30
Gone quiet Reached 3 outlets in its first 24 hours
Reports
5
Developments
1
Repetition
80%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

FDA approved BRINSUPRI as first treatment for non-cystic fibrosis bronchiectasis. Insmed application accepted in Japan for BRINSUPRI.

Who's involved

What this event is mainly about
FDAInsmedCedarPPF

Keep exploring

Part of

A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

Also in this story

All 83 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • prnewswire_fairwayInsmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
  • Pharmaceutical TechnologyInsmed scores pivotal win in bronchiectasis with FDA approval of Brinsupri The US Food and Drug Administration (FDA) approval of Insmed’s Brinsupri marks a significant advancement in the treatment la
  • Simply Wall St.How FDA Approval of BRINSUPRI for NCFB at Insmed (INSM) Has Changed Its Investment Story Insmed Incorporated recently announced that the U.S. Food and Drug Administration approved BRINSUPRI (brensoca
  • Simply Wall St.Insmed (INSM) Gains As FDA Approves BRINSUPRI For New Market Insmed saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FD
  • Pharmaceutical TechnologyInsmed wins FDA approval for future blockbuster Brinsupri Insmed's drug Brinsupri (brensocatib) has landed a double regulatory landmark win, becoming both the first marketed dipeptidyl peptidase 1 (D